MSI 測試市場：策略洞察與預測（2026-2035 年）

MSI 測試市場預計將從 2026 年的 6.011 億美元成長到 2035 年的 12.535 億美元，複合年成長率為 8.5%。

在以生物標記為基礎的免疫療法和精準腫瘤學的模式轉移驅動下，微衛星不穩定性（MSI）檢測市場正經歷重大變革。這一市場演變的特點是，人們日益認知到MSI狀態可作為預測免疫療法反應的生物標記，並為評估遺傳性癌症（尤其是疑似林奇症候群患者）提供寶貴資訊。先進的分子診斷平台、全面的基因組分析和人工智慧的融合，使得檢測由DNA錯配修復機制缺陷導致的微衛星區域突變變得更有效率。由於免疫查核點抑制劑療法的選擇直接取決於生物標記的準確性，醫療系統正日益將MSI檢測整合到常規診斷流程中。隨著腫瘤科醫師在啟動標靶治療前需要從單一患者檢體中獲得多種生物標記物，臨床實踐正轉向全面的基因組分析。這種轉變推動了對能夠與更廣泛的分子檢測工作流程無縫整合的MSI檢測方法的需求，從而在提高診斷效率的同時減少組織樣本的使用。隨著以生物標記為重點的臨床試驗不斷改進患者篩選並增強治療效果的證據，製藥公司持續將微衛星不穩定性（MSI）狀態納入其腫瘤研發項目中。監管機構日益重視分子診斷的分析有效性、臨床表現和標準化報告，鼓勵製造商投資於檢測方法的標準化、自動化和品質保證。隨著市場對基於新一代定序（NGS）的工作流程、基於液態生物檢體的MSI檢測以及人工智慧驅動的生物資訊學的大量投資，MSI檢測正逐漸成為多種固體癌類型全面基因組分析的核心組成部分。

市場促進因素

基於生物標記的免疫療法的日益普及是微衛星不穩定性（MSI）檢測市場的主要驅動力。免疫查核點抑制劑越來越依賴分子生物標記來識別最有可能獲得持續臨床療效的患者。因此，臨床腫瘤學正在將MSI檢測納入免疫治療前的常規診斷流程。由於治療合格直接取決於生物標記的準確性，這種依賴性推動了對高度標準化分子檢測的需求，從而導致MSI檢測應用範圍的持續擴大。精準腫瘤學臨床試驗的擴展進一步加速了市場成長。精準腫瘤學越來越依賴基因生物標記來對患者進行分層並改善治療效果。製藥公司正在將MSI檢測納入早期和晚期腫瘤臨床試驗，以增強基因選擇族群的臨床證據。這種方法降低了患者異質性，同時提高了監管申報的效率。診斷公司正透過合作開發檢測方法和進行多中心臨床檢驗研究來應對這一需求。全面基因組分析的日益普及推動了對整合診斷解決方案的需求。在癌症治療中，人們越來越需要同時評估多種生物標記物，而不是進行順序的單基因檢測。實驗室正在採用新一代定序（NGS）工作流程，除了微衛星不穩定性（MSI）評估外，還整合了腫瘤突變負荷（TMB）和具有治療意義的基因組突變。這種整合提高了組織利用效率並縮短了檢測時間。製造商不斷開發整合試劑組和軟體平台，以簡化基因組分析的解讀。監管機構對伴隨診斷的支持正在提升其臨床可信度和市場滲透率。監管機構認知到分子診斷是癌症個人化治療的關鍵要素。製造商正在尋求伴隨診斷的監管批准，以增強其臨床可信度和市場滲透率。這個不斷發展的框架正在推動對檢測方法標準化、分析性能和上市後證據生成的持續投資。

市場限制因素

資源匱乏的醫療體系難以獲得先進的分子診斷基礎設施，這持續限制微衛星不穩定性（MSI）檢測的普及。專業設備和專業知識所需的巨額投資，對發展中地區的小規模檢查室和機構而言是一大障礙。儘管越來越多的臨床證據支持基於生物標記的療法，但國家醫保覆蓋範圍的差異阻礙了其常規應用。不同醫療體系的健保政策各異，限制了病患獲得先進檢測方案的機會，也為診斷機構帶來了不確定性。檢查室間調查方法和標準的差異，仍然是標準化檢測方法和結果比較的挑戰。檢查室間缺乏標準化的操作規程，會導致結果不一致，並降低臨床可靠性。區域監管的複雜性也給尋求將新型檢測方案商業化的診斷試劑生產商帶來了合規負擔。不斷變化的監管環境要求企業持續調整，導致營運成本增加，新產品上市時間延長。

目錄

第1章執行摘要

• 市場概述
• 主要發現
• 分析師意見
• 策略建議

第2章：調查方法

• 調查設計
• 資料收集和調查方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章 全球MSI測試市場：概述、市場規模與預測

• 市場定義和範圍
• 微衛星不穩定性（MSI）測試概述
• 產業變化
• 主要市場趨勢
• 市場規模表現分析
• 市場預測
• MSI檢測的疾病負擔與臨床意義
• MSI相關癌症的流行病學
• 確診為MSI相關惡性腫瘤的患者數量
• 精準腫瘤學中生物標記檢測的現狀
• MSI檢測在不同類型癌症的臨床效用
• 伴隨診斷的現狀

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• MSI測試中的新興技術
• 產品創新
• 基於MSI的精準腫瘤學臨床試驗分析
• MSI診斷技術的流程分析
• 將人工智慧應用於分子診斷
• 數位病理學與次世代定序的整合

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章：全球微晶片測試市場：展望分析

• 分析：按技術平台
• 分析：按測試方法
• 分析：按癌症類型分類
• 分析：依樣本類型
• 分析：透過臨床應用
• 分析：按測試環境

第9章 全球MSI測試市場：細分市場分析

• 按產品/服務
  • 試劑盒和試劑
  • 裝置
  • 軟體和服務
• 透過技術
  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序（NGS）
  • 免疫組織化學（IHC）
  • 其他分子技術
• 依樣本類型
  • 組織樣本
  • 液態生物檢體
• 按癌症類型
  • 結腸癌
  • 子宮內膜癌
  • 胃癌
  • 卵巢癌
  • 攝護腺癌
  • 胰臟癌
  • 其他固體癌
• 臨床應用
  • 伴隨診斷
  • 遺傳風險評估
  • 免疫療法中的患者選擇
  • 其他
• 最終用戶
  • 醫院
  • 診斷檢查室
  • 癌症研究機構
  • 其他

第10章：全球MSI測試市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章：全球微感測器偵測市場：國別分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 日本
• 中國
• 印度
• 韓國
• 澳洲
• 巴西
• 墨西哥
• 沙烏地阿拉伯
• 南非

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 併購、合作與聯盟
• 新產品發布

第13章：公司簡介

• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN NV
• Thermo Fisher Scientific Inc.
• Promega Corporation
• Illumina, Inc.
• Merck & Co.
• Guardant Health
• Tempus Labs.
• Natera Inc.

第14章：全球微訊號整合測試市場：商業預測分析

第15章 投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

一個

The MSI Testing Market is expected to grow at a CAGR of 8.5% from a market value of USD 601.1 million in 2026 to USD 1,253.5 million in 2035.

The MSI testing market is undergoing significant transformation driven by the paradigm shift toward biomarker-guided immunotherapy and precision oncology. The market's evolution is characterized by the growing recognition that MSI status serves as a predictive biomarker for immunotherapy response and provides valuable information for hereditary cancer assessment, particularly in patients suspected of having Lynch syndrome. The convergence of advanced molecular diagnostic platforms, comprehensive genomic profiling, and artificial intelligence is enabling more efficient detection of alterations in microsatellite regions resulting from deficient DNA mismatch repair mechanisms. Healthcare systems are increasingly integrating MSI testing into routine diagnostic pathways because treatment selection for immune checkpoint inhibitors directly depends on biomarker accuracy. The clinical practice is shifting toward comprehensive genomic profiling because oncologists require multiple biomarkers from a single patient specimen before initiating targeted therapy. This transition is increasing demand for MSI assays that integrate seamlessly with broader molecular testing workflows, reducing tissue consumption while improving diagnostic efficiency. Pharmaceutical sponsors continue incorporating MSI status into oncology development programs because biomarker-enriched clinical trials improve patient selection and strengthen therapeutic evidence. Regulatory agencies increasingly emphasize analytical validity, clinical performance, and standardized reporting for molecular diagnostics, encouraging manufacturers to invest in assay harmonization, automation, and quality assurance. The market is witnessing significant investment in NGS-enabled workflows, liquid biopsy-based MSI assays, and AI-enabled bioinformatics, positioning MSI testing as a core component of comprehensive genomic profiling across multiple solid tumor types.

Market Drivers

The increasing adoption of biomarker-guided immunotherapy represents the primary driver for the MSI testing market. Immune checkpoint inhibitors increasingly rely on molecular biomarkers that identify patients most likely to achieve durable clinical responses. Oncology practices are consequently incorporating MSI testing into routine diagnostic pathways before initiating immunotherapy. This dependency strengthens demand for highly standardized molecular assays because treatment eligibility directly depends on biomarker accuracy, resulting in sustained growth in MSI testing utilization. The expansion of precision oncology clinical trials is further accelerating market growth. Precision oncology increasingly depends on genomic biomarkers to improve patient stratification and therapeutic outcomes. Pharmaceutical sponsors are incorporating MSI testing throughout early- and late-stage oncology trials because genetically selected populations strengthen clinical evidence. This approach reduces patient heterogeneity while supporting more efficient regulatory submissions. Diagnostic companies are responding through collaborative assay development and multicenter clinical validation studies. The growing adoption of comprehensive genomic profiling is driving demand for integrated testing solutions. Cancer management increasingly requires simultaneous evaluation of multiple biomarkers rather than sequential single-gene testing. Laboratories are adopting NGS workflows that integrate MSI assessment alongside tumor mutational burden and actionable genomic variants. This consolidation improves tissue utilization while reducing testing turnaround time. Manufacturers continue developing integrated reagent kits and software platforms that simplify genomic interpretation. Regulatory support for companion diagnostics is strengthening clinical confidence and commercial adoption. Regulatory agencies recognize molecular diagnostics as essential components of personalized oncology. Manufacturers are pursuing companion diagnostic approvals because regulatory recognition strengthens clinical confidence and commercial adoption. These evolving frameworks encourage continuous investment in assay standardization, analytical performance, and post-market evidence generation.

Market Restraints

Limited access to advanced molecular diagnostic infrastructure continues to restrict MSI testing adoption in resource-constrained healthcare systems. The significant investment needed for specialized equipment and expertise creates barriers for smaller laboratories and facilities in developing regions. Variability in reimbursement coverage across countries slows routine implementation despite growing clinical evidence supporting biomarker-guided therapy. Inconsistent coverage policies across different healthcare systems limit patient access to advanced testing options and create uncertainty for diagnostic providers. Differences in laboratory methodologies and interpretation criteria continue to create challenges for assay standardization and result comparability. The lack of standardized protocols across different laboratories can lead to inconsistent results and reduced clinical confidence. Regulatory complexities across different jurisdictions create compliance burdens for diagnostic manufacturers seeking to commercialize new testing solutions. The evolving regulatory landscape requires continuous adaptation, increasing operational costs and time-to-market for new products.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated molecular testing platforms. Clinical laboratories are increasingly adopting NGS workflows that integrate MSI assessment alongside tumor mutational burden and actionable genomic variants because this consolidation improves tissue utilization while reducing testing turnaround time. PCR-based technologies remain widely utilized for focused MSI detection where rapid turnaround and cost-effectiveness are priorities. IHC-based MMR testing continues supporting established protein assessment for mismatch repair deficiency. Digital PCR and liquid biopsy technologies are emerging as complementary approaches for minimally invasive MSI assessment. The segment analysis reveals that kits and reagents constitute the largest demand segment because every MSI analysis requires validated consumables, irrespective of the testing platform. Clinical laboratories are increasingly adopting standardized reagent kits that simplify workflow validation while improving analytical reproducibility. Colorectal cancer represents the primary clinical application because international treatment guidelines recommend universal assessment for newly diagnosed patients. Healthcare providers are increasingly integrating MSI status into routine diagnostic pathways because it simultaneously supports Lynch syndrome screening, prognostic evaluation, and immunotherapy selection. Endometrial cancer is also experiencing increasing testing adoption because universal MMR or MSI screening is becoming integrated into routine pathological evaluation. Companion diagnostics are becoming the fastest-evolving application because oncology drug development increasingly depends on validated predictive biomarkers. Pharmaceutical companies are incorporating MSI testing throughout clinical development programs to identify patients most likely to respond to immunotherapy. Diagnostic laboratories and hospitals represent key end-user segments, with cancer research institutes playing an increasingly important role in clinical validation. The integration of artificial intelligence is becoming increasingly important because increasing genomic data complexity requires scalable interpretation tools that support clinical decision-making. AI-enabled bioinformatics are improving reporting accuracy and workflow efficiency while reducing analytical variability.

Competitive and Strategic Outlook

The competitive landscape features established molecular diagnostics companies alongside specialized precision oncology providers. Agilent Technologies is strengthening its position through its integrated pathology and molecular diagnostics portfolio, including Dako IHC assays and genomics solutions that support MMR assessment. F. Hoffmann-La Roche maintains a leading position by combining pharmaceutical expertise with advanced tissue diagnostics, with its VENTANA MMR IHC assays and companion diagnostic portfolio supporting biomarker-guided cancer treatment. QIAGEN focuses on molecular diagnostics and companion diagnostic development through its sample preparation technologies, digital PCR systems, and sequencing solutions. Thermo Fisher Scientific supports MSI testing through its Ion Torrent sequencing platforms, Oncomine assays, and clinical bioinformatics solutions that enable comprehensive genomic profiling. Illumina remains a global leader in NGS by providing sequencing platforms and oncology assays that facilitate integrated MSI analysis. Guardant Health differentiates itself through liquid biopsy technologies that enable non-invasive comprehensive genomic profiling, including MSI assessment in advanced cancers. Promega Corporation is recognized for the OncoMate MSI Dx Analysis System, which received FDA approval as a companion diagnostic for identifying patients with microsatellite stable endometrial carcinoma who may benefit from treatment with KEYTRUDA plus LENVIMA. Companies are pursuing product portfolio expansion through innovation in NGS-enabled workflows, liquid biopsy-based MSI assays, and AI-enabled bioinformatics. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside immunotherapies. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing emerging markets. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities.

Short Conclusion

The MSI testing market is positioned for sustained growth driven by the convergence of biomarker-guided immunotherapy, comprehensive genomic profiling, and expanding healthcare investment. The transition from a single biomarker assay to a core component of comprehensive genomic profiling represents a fundamental shift in precision oncology diagnostics. While challenges related to limited infrastructure, reimbursement variability, and assay standardization persist, strategic investments in technology, clinical validation, and regulatory compliance are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with MSI testing evolving into an essential component of precision oncology across multiple solid tumor types, supporting immunotherapy patient selection, hereditary cancer assessment, and companion diagnostic development.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global MSI Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Overview of Microsatellite Instability (MSI) Testing
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Burden and Clinical Significance of MSI Testing
• 3.8 Epidemiology of MSI-Associated Cancers
• 3.9 Diagnosed Patient Population for MSI-Associated Malignancies
• 3.10 Biomarker Testing Landscape in Precision Oncology
• 3.11 Clinical Utility of MSI Testing Across Cancer Types
• 3.12 Companion Diagnostics Landscape

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in MSI Testing
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis for MSI-Driven Precision Oncology
• 6.4 Pipeline Analysis of MSI Diagnostic Technologies
• 6.5 AI Integration in Molecular Diagnostics
• 6.6 Digital Pathology and Next-Generation Sequencing Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global MSI Testing Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Testing Methodology
• 8.3 Analysis by Cancer Type
• 8.4 Analysis by Sample Type
• 8.5 Analysis by Clinical Application
• 8.6 Analysis by Testing Setting

9. Global MSI Testing Market Segment Analysis (2021-2035)

• 9.1 By Product & Service
  • 9.1.1 Kits & Reagents
  • 9.1.2 Instruments
  • 9.1.3 Software & Services
• 9.2 By Technology
  • 9.2.1 Polymerase Chain Reaction (PCR)
  • 9.2.2 Next-Generation Sequencing (NGS)
  • 9.2.3 Immunohistochemistry (IHC)
  • 9.2.4 Other Molecular Technologies
• 9.3 By Sample Type
  • 9.3.1 Tissue Samples
  • 9.3.2 Liquid Biopsy
• 9.4 By Cancer Type
  • 9.4.1 Colorectal Cancer
  • 9.4.2 Endometrial Cancer
  • 9.4.3 Gastric Cancer
  • 9.4.4 Ovarian Cancer
  • 9.4.5 Prostate Cancer
  • 9.4.6 Pancreatic Cancer
  • 9.4.7 Other Solid Tumors
• 9.5 By Clinical Application
  • 9.5.1 Companion Diagnostics
  • 9.5.2 Hereditary Risk Assessment
  • 9.5.3 Immunotherapy Patient Selection
  • 9.5.4 Others
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Diagnostic Laboratories
  • 9.6.3 Cancer Research Institutes
  • 9.6.4 Others

10. Global MSI Testing Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global MSI Testing Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Agilent Technologies, Inc.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 F. Hoffmann-La Roche Ltd.
• 13.3 QIAGEN N.V.
• 13.4 Thermo Fisher Scientific Inc.
• 13.5 Promega Corporation
• 13.6 Illumina, Inc.
• 13.7 Merck & Co.
• 13.8 Guardant Health
• 13.9 Tempus Labs.
• 13.10 Natera Inc.

14. Global MSI Testing Market Commercial Forecast Analysis

• 14.1 Commercial Forecast by Technology Platform
• 14.2 Commercial Forecast by Product & Service
• 14.3 Commercial Forecast by Clinical Application
• 14.4 Commercial Forecast by Cancer Type
• 14.5 Commercial Forecast by End User

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends

a